How enforcement, settlement posture, and leverage change once the first generic or biosimilar has already entered the market.
Discuss disputes where manufacturing processes, scale, or technical constraints ultimately dictated infringement and validity outcomes.
A focused look at litigating patents in India where manufacturing scale, pricing pressure, and public-interest arguments materially affect outcomes.
A practical discussion on how in-house teams decide not to sue despite apparent infringement. Focused on risk, cost, precedent, and internal decision-making rather than legal theory.
How patent disputes reveal weaknesses in claim drafting and specification support, and how litigation outcomes are reshaping prosecution strategy for device portfolios.
Olivier Marchand
Regenerative Agriculture Manager
Nestlé
Olivier Marchand is Regenerative Agriculture Manager at Nestlé, with over 20 years of experience driving sustainability, quality, and responsible practices across value chains.
With a strong background in purchasing, quality assurance, and agriculture, he has worked across Europe, Africa, Latin America, and Asia, bringing a global and cross-cultural perspective. He focuses on strengthening traceability, sustainability, and trust, helping meet growing consumer expectations around product origin, production methods, and social responsibility.
Sébastien Roumegous
CEO
BIOSPHERES
Sébastien Roumegous is a soil specialist and impact entrepreneur focused on scaling regenerative agriculture. As CEO of BIOSPHERES, Europe’s leading regenerative agriculture company, he supports businesses and public actors in transitioning toward high-performing, ecosystem-restoring farming systems.
With over 15 years of experience across 22 countries and 200,000 hectares in transition, his work combines technical expertise with a pragmatic, field-driven approach to improve soil health, biodiversity, and farmers’ livelihoods. Raised in a farming environment in southern France, he brings a grounded, results-oriented perspective to large-scale agricultural transformation. He recently published his first book on regenerative agriculture.
How MedTech companies assess exposure to standard essential patents as connectivity standards become embedded in devices, including licensing strategy and litigation risk.
How MedTech companies decide when to patent device innovation and when to rely on trade secret protection, balancing enforcement leverage, disclosure risk, and reverse engineering realities.
Eda Stark
Global IP Transactions & Litigation Managing Counsel
Olympus
Gabriel Olander
Associate GC, IP Strategy
Intuitive
How and why US-based companies are using Brazilian litigation as part of their cross-border enforcement and settlement strategies, including the ease of injunctions, speed and increasing success in tech-based cases.